PREVEnt Trial: Prevention of Rupture with Enzastaurin in Vascular Ehlers-Danlos Syndrome

PREVEnt Trial

“Prevention of Rupture with Enzastaurin in Vascular Ehlers-Danlos Syndrome”

Aytu BioPharma, Inc. will be sponsoring an upcoming clinical trial to evaluate the effectiveness of AR101 (enzastaurin) in preventing cardiac or arterial events in patients with:

Vascular Ehlers-Danlos Syndrome (VEDS)

Confirmed COL3A1 gene mutation

To find out more about this trial, simply fill out the form below.

*Required fields
Name*
First Last
Title
Company/Institution
Email*
Telephone*
Preferred contact method:*
- Email
- Telephone
Address*
Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country
Reason for Inquiring?*
Please specify
Opt-in*
- By checking this box and clicking SUBMIT below, I confirm I’m at least 18 years old; confirm I agree to Aytu BioPharma’s Privacy Policy; and consent to Aytu BioPharma, its successors, agents, and/or assigns using the email address provided to directly contact me regarding my eligibility for the PREVEnt study.
Disclaimer: Please note the information you enter will be kept private, except when ordered by law, and only accessible to our Clinical Research Partners and affiliates and applicable regulatory agencies. If you have any questions regarding the handling of the information you have provided, or if you would like to make any changes, please contact us at vedstrial@aytubio.com.

PREVEnt Trial: Prevention of Rupture with Enzastaurin in Vascular Ehlers-Danlos Syndrome

PREVEnt Trial

“Prevention of Rupture with Enzastaurin in Vascular Ehlers-Danlos Syndrome”

Share this study: